Astellas Pharma US will stop distributing Xtandi, a prostate cancer drug that costs about $160,000 each year, to 340B contract pharmacies on Sept. 1, according to a letter obtained by 340B Health.
Johnstown (Colo.) Heights Behavioral Health has been hit with an immediate jeopardy citation, the second one it has been issued since November 2022, ABC affiliate KMGH reported July 4.
The FDA has rejected Amneal Pharmaceuticals’ new drug application for IPX203, which the company hoped would be approved for treatment of Parkinson’s disease.
As artificial intelligence and generative AI such as ChatGPT continue to make headways into hospitals and health systems, more organizations are realizing the importance of hiring chief AI officers and advisers, as they can help their enterprises align…